These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 8627506

  • 21. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection.
    Ahuja SS, Reddick RL, Sato N, Montalbo E, Kostecki V, Zhao W, Dolan MJ, Melby PC, Ahuja SK.
    J Immunol; 1999 Oct 01; 163(7):3890-7. PubMed ID: 10490989
    [Abstract] [Full Text] [Related]

  • 22. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

  • 23. Comparative susceptibility of African green monkeys (Cercopithecus aethiops) to experimental infection with Leishmania leishmania donovani and Leishmania leishmania infantum.
    Binhazim AA, Shin SS, Chapman WL, Olobo J.
    Lab Anim Sci; 1993 Feb 12; 43(1):37-47. PubMed ID: 8459677
    [Abstract] [Full Text] [Related]

  • 24. Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens.
    Afrin F, Ali N.
    J Parasitol; 1998 Aug 12; 84(4):743-8. PubMed ID: 9714204
    [Abstract] [Full Text] [Related]

  • 25. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
    Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, Heinzel FP.
    J Infect Dis; 2003 Aug 01; 188(3):458-64. PubMed ID: 12870129
    [Abstract] [Full Text] [Related]

  • 26. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M, Bhattacharyya A, Duttagupta S.
    Med Sci Monit; 2002 Apr 01; 8(4):BR117-22. PubMed ID: 11951057
    [Abstract] [Full Text] [Related]

  • 27. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
    Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, Sahasrabuddhe AA, Dube A.
    J Immunol; 2009 Jul 01; 183(1):470-9. PubMed ID: 19542458
    [Abstract] [Full Text] [Related]

  • 28. Effect of immunization with lipid associated polysaccharide antigen and anti CD-2 antibodies on class II MHC expression and cellular immune response in BALB/C mice infected with Leishmania donovani.
    Bimal S, Bagchi AK, Das V, Sinha PK, Lal CS, Ranjan A, Gupta AK, Kar SK.
    Indian J Exp Biol; 2001 Sep 01; 39(9):878-82. PubMed ID: 11831368
    [Abstract] [Full Text] [Related]

  • 29. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
    Narayan S, Bimal S, Singh SK, Gupta AK, Singh VP, Sinha PK, Das P.
    Exp Parasitol; 2009 Jan 01; 121(1):69-75. PubMed ID: 18948098
    [Abstract] [Full Text] [Related]

  • 30. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.
    Murray HW, Xiang Z, Ma X.
    Am J Trop Med Hyg; 2006 Jun 01; 74(6):1013-5. PubMed ID: 16760512
    [Abstract] [Full Text] [Related]

  • 31. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbiéri CL, Uliana SR.
    J Antimicrob Chemother; 2009 Feb 01; 63(2):365-8. PubMed ID: 19095684
    [Abstract] [Full Text] [Related]

  • 32. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection.
    Melby PC, Tabares A, Restrepo BI, Cardona AE, McGuff HS, Teale JM.
    Exp Parasitol; 2001 Sep 01; 99(1):17-25. PubMed ID: 11708830
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.
    Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, McFarlane E.
    Vaccine; 2007 May 30; 25(22):4502-9. PubMed ID: 17418459
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P, Saxena S, Madhubala R.
    Vaccine; 2006 Mar 20; 24(13):2409-16. PubMed ID: 16413950
    [Abstract] [Full Text] [Related]

  • 38. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S, Vasishta RK, Arora SK.
    Exp Parasitol; 2009 Jan 20; 121(1):29-37. PubMed ID: 18983842
    [Abstract] [Full Text] [Related]

  • 39. STAT4 is critical for immunity but not for antileishmanial activity of antimonials in experimental visceral leishmaniasis.
    Oghumu S, Gupta G, Snider HM, Varikuti S, Terrazas CA, Papenfuss TL, Kaplan MH, Satoskar AR.
    Eur J Immunol; 2014 Feb 20; 44(2):450-9. PubMed ID: 24242758
    [Abstract] [Full Text] [Related]

  • 40. Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.
    Murray HW.
    Infect Immun; 2008 Sep 20; 76(9):4088-91. PubMed ID: 18573898
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.